Alessio Nocentini, Anna Di Porzio, Alessandro Bonardi, Carla Bazzicalupi, Andrea Petreni, Tarita Biver, Silvia Bua, Simona Marzano, Jussara Amato, Bruno Pagano, Nunzia Iaccarino, Stefano De Tito, Stefano Amente, Claudiu T Supuran, Antonio Randazzo, Paola Gratteri
{"title":"Development of a multi-targeted chemotherapeutic approach based on G-quadruplex stabilisation and carbonic anhydrase inhibition.","authors":"Alessio Nocentini, Anna Di Porzio, Alessandro Bonardi, Carla Bazzicalupi, Andrea Petreni, Tarita Biver, Silvia Bua, Simona Marzano, Jussara Amato, Bruno Pagano, Nunzia Iaccarino, Stefano De Tito, Stefano Amente, Claudiu T Supuran, Antonio Randazzo, Paola Gratteri","doi":"10.1080/14756366.2024.2366236","DOIUrl":null,"url":null,"abstract":"<p><p>A novel class of compounds designed to hit two anti-tumour targets, G-quadruplex structures and human carbonic anhydrases (hCAs) IX and XII is proposed. The induction/stabilisation of G-quadruplex structures by small molecules has emerged as an anticancer strategy, disrupting telomere maintenance and reducing oncogene expression. hCAs IX and XII are well-established anti-tumour targets, upregulated in many hypoxic tumours and contributing to metastasis. The ligands reported feature a berberine G-quadruplex stabiliser scaffold connected to a moiety inhibiting hCAs IX and XII. <i>In vitro</i> experiments showed that our compounds selectively stabilise G-quadruplex structures and inhibit hCAs IX and XII. The crystal structure of a telomeric G-quadruplex in complex with one of these ligands was obtained, shedding light on the ligand/target interaction mode. The most promising ligands showed significant cytotoxicity against CA IX-positive HeLa cancer cells in hypoxia, and the ability to stabilise G-quadruplexes within tumour cells.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11195807/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Enzyme Inhibition and Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14756366.2024.2366236","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A novel class of compounds designed to hit two anti-tumour targets, G-quadruplex structures and human carbonic anhydrases (hCAs) IX and XII is proposed. The induction/stabilisation of G-quadruplex structures by small molecules has emerged as an anticancer strategy, disrupting telomere maintenance and reducing oncogene expression. hCAs IX and XII are well-established anti-tumour targets, upregulated in many hypoxic tumours and contributing to metastasis. The ligands reported feature a berberine G-quadruplex stabiliser scaffold connected to a moiety inhibiting hCAs IX and XII. In vitro experiments showed that our compounds selectively stabilise G-quadruplex structures and inhibit hCAs IX and XII. The crystal structure of a telomeric G-quadruplex in complex with one of these ligands was obtained, shedding light on the ligand/target interaction mode. The most promising ligands showed significant cytotoxicity against CA IX-positive HeLa cancer cells in hypoxia, and the ability to stabilise G-quadruplexes within tumour cells.
本研究提出了一类新型化合物,旨在打击两个抗肿瘤靶点--G-四叠体结构和人类碳酸酐酶(hCAs)IX 和 XII。小分子诱导/稳定 G 型四叠体结构已成为一种抗癌策略,可破坏端粒的维持并减少癌基因的表达。hCAs IX 和 XII 是公认的抗肿瘤靶点,在许多缺氧性肿瘤中上调并导致转移。报告中的配体具有小檗碱 G-四联体稳定剂支架,与抑制 hCAs IX 和 XII 的分子相连。体外实验表明,我们的化合物能选择性地稳定 G-四叉结构并抑制 hCAs IX 和 XII。我们还获得了端粒 G-四叉体与其中一种配体复合物的晶体结构,从而揭示了配体与目标的相互作用模式。最有希望的配体对缺氧条件下的 CA IX 阳性 HeLa 癌细胞具有显著的细胞毒性,并能稳定肿瘤细胞内的 G-四联体。
期刊介绍:
Journal of Enzyme Inhibition and Medicinal Chemistry publishes open access research on enzyme inhibitors, inhibitory processes, and agonist/antagonist receptor interactions in the development of medicinal and anti-cancer agents.
Journal of Enzyme Inhibition and Medicinal Chemistry aims to provide an international and interdisciplinary platform for the latest findings in enzyme inhibition research.
The journal’s focus includes current developments in:
Enzymology;
Cell biology;
Chemical biology;
Microbiology;
Physiology;
Pharmacology leading to drug design;
Molecular recognition processes;
Distribution and metabolism of biologically active compounds.